RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY

Plain-language summary

This observational study evaluates the radiological and clinical outcomes of renal embolization performed with a substance called EVOH in dialysis patients who have autosomal dominant polycystic kidney disease. Patients aged 18 to 75 with a kidney volume between 2000 and 5000 mL who are on dialysis and undergoing renal embolization may take part. It is a study without a phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Start date

8/17/2020

Estimated completion

8/17/2026

Countries

Italy

Related genes

Locations

• Pavia, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* aged over 18 and under 75
* written informed consent
* Patients with autosomal dominant polycystic kidney disease, with a kidney volume of between 2000 and 5000 mL, on dialysis, undergoing renal embolisation

Exclusion Criteria:

• Contraindications to MRI without contrast (ferromagnetic implants, incompatible pacemakers, surgical clips, severe claustrophobia or other conditions that may interfere with MRI)